You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,526,734

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,526,734 protect, and when does it expire?

Patent 9,526,734 protects VIVLODEX and is included in one NDA.

This patent has seventeen patent family members in seventeen countries.

Summary for Patent: 9,526,734
Title:Formulation of meloxicam
Abstract: Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam.
Inventor(s): Bosch; H. William (Bryn Mawr, PA)
Assignee: iCeutica Pty Ltd. (Balcatta WA, AU)
Application Number:14/675,410
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,526,734
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,526,734

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Zyla VIVLODEX meloxicam CAPSULE;ORAL 207233-001 Oct 22, 2015 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Zyla VIVLODEX meloxicam CAPSULE;ORAL 207233-002 Oct 22, 2015 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,526,734

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015274838   Start Trial
Brazil 112016027435   Start Trial
Canada 2951383   Start Trial
China 107073010   Start Trial
Eurasian Patent Organization 201692392   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.